Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Clinical testing of the preparation cystophos (monosodium salt of beta- aminoethyl thiophosphoric acid) (in German)

Journal Article · · Radiobiol.-Radiother., v. 14, no. 6, pp. 671-676
OSTI ID:4327712
The results of clinical testing of the radioprotective substance cystaphos (monosodium salt of beta-aminoethyl thiophosphoric acid) is represented. The preparation was administered to mamma carcinoma and portio carcinoma patients before the irradiation period. The data obtained showed symptoms of a general radiation reaction as to nausea, headache, sleeplessness, and so on to occur much more seldom among patients having received cystaphos. The preparation had no protective influence on the development of radiation leukopenia with radiation therapy, it guaranteed, however, a more rapid regeneration of the whole leukocyte amount after termination of the treatment compared with the starting values existing before irradiation. Radiation leukopenia developed to the same extent in patients having received cystaphos and in patients without uptake of cystaphos. The radioprotective substance obviously protected thrombocytes against the injurious effect of ionizing radiation. In patients having received cystaphos, a thrombocytopenia did not develop during radiation therapy that was characteristic of the control patients, i.e., who were treated without the radioprotective substance. The regression of the tumorous process under the influence of radiation therapy was the same in patients without its uptake. (auth)
Research Organization:
Originating Research Org. not identified
NSA Number:
NSA-29-027058
OSTI ID:
4327712
Journal Information:
Radiobiol.-Radiother., v. 14, no. 6, pp. 671-676, Journal Name: Radiobiol.-Radiother., v. 14, no. 6, pp. 671-676; ISSN RDBGA
Country of Publication:
Country unknown/Code not available
Language:
German